For informational and research purposes only. Not medical advice. Content is aggregated from public sources. Always consult a qualified healthcare provider.
Performance & Growth Hormone · Comparison

IGF-1 LR3 vs PEG-MGF

A neutral, side-by-side comparison of two performance & growth hormone peptides — their mechanisms, dosing ranges, administration routes, side effects, and research evidence. For research and educational purposes only.

IGF-1 LR3PEG-MGF
CategoryPerformance & Growth HormonePerformance & Growth Hormone
Also known asInsulin-like Growth Factor-1 Long R3, Long R3 IGF-1, Increlex (human equivalent)PEGylated Mechano Growth Factor, Polyethylene Glycol-MGF, Long-acting MGF
EvidenceResearch-stagePreclinical only
Dosing range20mcg–100mcg mcg, Once daily post-workout, on training days only (common protocol)100mcg–400mcg mcg, 2x weekly (Monday/Thursday or similar split)
AdministrationSubcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols)Subcutaneous injection (preferred for systemic distribution), Intramuscular injection
Key side effectsHypoglycemia (clinically significant — monitor blood sugar carefully), Jaw and organ growth with chronic high-dose use (theoretical at research doses), Fatigue and headaches, Joint painHypoglycemia (less pronounced than IGF-1 DES, more than native MGF due to systemic distribution), Generalized fatigue on injection days, PEG accumulation concern with very high doses over long periods (theoretical — not established at research doses), Localized injection site swelling
Cited sources3 references2 references

Key differences

  • Evidence level differs: IGF-1 LR3 is research-stage, while PEG-MGF is preclinical only.
  • Administration: IGF-1 LR3 — Subcutaneous injection, Intramuscular injection (into the trained muscle — site-specific protocols); PEG-MGF — Subcutaneous injection (preferred for systemic distribution), Intramuscular injection.
  • Frequency: IGF-1 LR3 is typically Once daily post-workout, on training days only (common protocol); PEG-MGF is 2x weekly (Monday/Thursday or similar split).
  • Research depth: this profile cites 3 sources for IGF-1 LR3 vs 2 for PEG-MGF.

How each works

IGF-1 LR3

In vitro and animal research establishes IGF-1 LR3 as a potent anabolic and growth-promoting agent. It activates the IGF-1 receptor (IGF-1R) and downstream PI3K/Akt and MAPK/Erk pathways, promoting skeletal muscle hypertrophy and satellite cell activation. Its extended half-life makes it far more active systemically than native IGF-1. Research also documents its role in connective tissue repair, nerve regeneration, and fat oxidation. Human research is limited — most data comes from cancer cell biology and athletic performance settings.

PEG-MGF

PEGylation is a validated pharmaceutical strategy for extending peptide half-life (used in Pegasys/interferon, Somavert/pegvisomant, and others). The PEG chain shields the MGF peptide from proteolytic degradation and slows renal clearance. Research in rodent models confirms PEG-MGF preserves the biological activity of native MGF (satellite cell activation, muscle repair) with extended duration. Unlike native MGF which requires precise post-workout injection timing, PEG-MGF can be injected on a scheduled basis and still achieves systemic muscle-wide satellite cell effects.

Read the full IGF-1 LR3 profileRead the full PEG-MGF profile

This comparison aggregates public research and structured profile data for informational purposes only. It is not medical advice and does not recommend either compound for human use. Consult a qualified healthcare provider before considering any peptide.